Your browser doesn't support javascript.
loading
Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.
Busch, A; Zeh, D; Janzen, V; Mügge, L-O; Wolf, D; Fingerhut, L; Hahn-Ast, C; Maurer, O; Brossart, P; von Lilienfeld-Toal, M.
Affiliation
  • Busch A; Department of Hematology, Oncology and Rheumatology, University Hospital Bonn, Bonn.
Clin Exp Immunol ; 177(2): 439-53, 2014 Aug.
Article in En | MEDLINE | ID: mdl-24712857
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Immunomodulation / Immunologic Factors / Multiple Myeloma Type of study: Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Exp Immunol Year: 2014 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Immunomodulation / Immunologic Factors / Multiple Myeloma Type of study: Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Exp Immunol Year: 2014 Document type: Article